Yahoo Finance

Aphaia Pharma Announces Positive Results from Phase 2 Trial Evaluating its Lead Drug Formulation for Prediabetes Treatment

ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, June 20, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous ...
Yahoo Finance

Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase

ZUG, Switzerland, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of ...
Yahoo Finance

Aphaia Pharma to Participate in a Panel Discussion at the 1st Annual Obesity & Metabolic Innovation Forum

Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the ...
manilatimes

Aphaia Pharma Publishes Phase 1 and 2 Clinical Data of Oral Formulation in Patients with Obesity and Prediabetes

Aphaia’s lead formulation orchestrates a comprehensive hormonal response from nutrient-sensing cells with potential to modify the course of obesity and associated metabolic diseases. It is currently ...
Business Insider

Aphaia Pharma to Participate in Panel Discussion at SXSW 2025

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous ...
Business Insider

Aphaia Pharma Initiates Second Phase 2 Trial of Oral Candidate in Obesity

Second Phase 2 trial builds on encouraging initial results from a prior Phase 2 study Aphaia’s formulation activates gastrointestinal nutrient-sensing signaling pathways to modify the course of ...